Humanized antibodies that bind LGR5

US9546214B2 · kind B2 · utility

Assignee

• Bionomics Limited · AU

Inventors

• Christopher L. Reyes · Adelaide, AU
• Peter Chu · Hawthorne, US
• Kristen M. Smith · San Clemente, US
• Lioudmila A. Campbell · San Diego, US
• Farbod Shojaei · San Diego, US
• John Norton · San Diego, US

Key dates

• Filing date: Apr 2, 2015
• Grant date: Jan 17, 2017
• Expiry date: Apr 2, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.